#China #Shanghai #biopharmaceuticals #Harbour BioMed #Stock Connect

Introduction

Harbour BioMed has recently reached a notable milestone by becoming part of the eligible shares in the Stock Connect program. This inclusion allows qualified investors from mainland China to engage directly with the company's shares through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect avenues. This event underscores a positive shift in capital market recognition for the company and signals its growing importance in the biotechnology landscape.

Significance of Inclusion

The addition of Harbour BioMed to the Stock Connect is a pivotal moment in its journey. It reflects the company's successful achievement of surpassing the HK$10 billion market capitalization threshold, placing it among large- and mid-cap biopharmaceutical enterprises traded on the Hong Kong stock exchange. This recognition is not only a testament to the firm’s impressive growth trajectory and research and development momentum but also highlights the strategic execution that has garnered market support.

Financial Performance

In the first half of 2026, Harbour BioMed reported impressive financial results, recording a total revenue of approximately US$122.5 million, which is a substantial 20.9% increase year-over-year. The adjusted net profit for the same period reached about US$71.6 million, marking seven consecutive profitable half-years. This achievement confirms the company’s transition into a phase of normalized profitability, reinforcing the sustainability of its business model within the biopharmaceutical sector. As of June 30, 2026, Harbour BioMed holds cash and cash equivalents amounting to approximately US$359.2 million, reflecting solid financial stability and flexibility to support its ongoing strategic initiatives.

Expanding Pipeline

The company boasts an extensive pipeline of nearly 30 differentiated drug candidates spanning various therapeutic areas including immunology, oncology, metabolism, and central nervous system disorders. Some of these candidates are already in clinical trials or have progressed into regulatory submission stages, demonstrating the company’s robust research capabilities. Notably, Batoclimab (HBM9161), Harbour's leading asset, is under review for Biologics License Application (BLA), poised for potential success across multiple autoimmune conditions. Additionally, Porustobart (HBM4003) has shown promising efficacy and safety signals in its clinical studies targeting advanced solid tumors.

HBM9378, a next-generation anti-TSLP monoclonal antibody, recently made notable progress with successful Phase II study initiations for chronic obstructive pulmonary disease (COPD) treatment and is expected to advance into further clinical evaluations in asthma by late 2026.

Strategic Partnerships and Collaborations

Demonstrating its ability to leverage strategic partnerships, Harbour BioMed has secured various licensing agreements to expand its geographical footprint. Notable deals include the out-licensing of rights for HBM9378 to Windward Bio, further affirming the company’s aptness in unlocking the global value of its biopharmaceutical pipeline through innovative and diversified collaboration models.

Commitment to Innovation

The company’s commitment to innovation is strongly backed by its industry-leading Harbour Mice® platform for fully human antibody generation. This proprietary technology catalyzes advancements in the field, and the establishment of its AI-driven drug discovery system represents a significant leap in efficiency and precision within the antibody development process.

Future Growth and Market Position

With its recent inclusion in the Stock Connect program, Harbour BioMed anticipates broader engagement from new investors, enhanced stock liquidity, and heightened visibility in the capital markets. This evolution not only improves the company's market dynamic but also supports a diversified investor base vital for its continuous growth.

Dr. Jingsong Wang, the company’s founder and CEO, articulated the significance of this inclusion, framing it as an essential milestone in market recognition and commitment to fostering innovation and partnerships that drive long-term value for shareholders.

Conclusion

Harbour BioMed stands at the forefront of biopharmaceutical innovation with a clear growth strategy powered by compelling financial results, a diverse drug pipeline, and robust collaborations. As it ventures into a new chapter marked by enhanced market visibility and investor interest, the company is poised for remarkable advancements in the biopharmaceutical industry and beyond.